CSL Ltd
CSL
Company Profile
Business description
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
32,000
Stocks News & Analysis
personal-finance
Why I was probably too quick to dismiss passive investing
Weighing up different approaches to investing is not a case of one being right and the other being wrong.
stocks
12 picks for an income portfolio - Q2 2025 update
One year in and passive income growth has exceeded my target.
stocks
ASX healthcare leader undervalued after share slump
The sell-off in this moated healthcare company ignores strong potential for revenue growth and margin improvement.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.60 | 4.90 | 0.06% |
| CAC 40 | 7,754.55 | 16.13 | 0.21% |
| DAX 40 | 23,934.13 | 144.02 | 0.61% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,823.20 | 48.51 | 0.55% |
| HKSE | 24,069.94 | 151.47 | -0.63% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,994.64 | 208.74 | 0.52% |
| NZX 50 Index | 12,719.23 | 14.75 | 0.12% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,595.80 | 1.90 | -0.02% |
| SSE Composite Index | 3,461.15 | 6.36 | 0.18% |